Author/Authors :
Bruce A. Ellsworth، نويسنده , , Wei Meng، نويسنده , , Manorama Patel، نويسنده , , Ravindar N. Girotra، نويسنده , , Gang Wu، نويسنده , , Philip M. Sher، نويسنده , , Deborah L. Hagan، نويسنده , , Mary T. Obermeier، نويسنده , , William G. Humphreys، نويسنده , , James G. Robertson، نويسنده , , Aiying Wang، نويسنده , , Songping Han، نويسنده , , Thomas L. Waldron، نويسنده , , Nathan N. Morgan، نويسنده , , Jean M. Whaley، نويسنده , , William N. Washburn، نويسنده ,
Abstract :
Inhibition of sodium-dependent glucose transporter 2 (SGLT2), the transporter that is responsible for renal re-uptake of glucose, leads to glucosuria in animals. SGLT-mediated glucosuria provides a mechanism to shed excess plasma glucose to ameliorate diabetes-related hyperglycemia and associated complications. The current study demonstrates that the proper relationship of a 4′-substituted benzyl group to a β-1C-phenylglucoside is important for potent and selective SGLT2 inhibition. The lead C-arylglucoside (7a) demonstrates superior metabolic stability to its O-arylglucoside counterpart (4) and it promotes glucosuria when administered in vivo.
Keywords :
SGLT , SGLT2 , Sodium-dependent glucose transporter , Hyperglycemia , glucosuria , Phlorizin , diabetes , metabolism , Glucosidase , Metabolic diseases , NIDDM , Dapagliflozin , C-Glucoside , C-Arylglucoside , Glucosidase